|Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies|
M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ...
Journal of clinical oncology 19 (13), 3267-3279, 2001
|Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …|
D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu
Journal of clinical oncology 22 (1), 77-85, 2004
|Tumour heterogeneity in the clinic|
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
|The statins as anticancer agents|
KKW Chan, AM Oza, LL Siu
Clinical cancer research 9 (1), 10-19, 2003
|Dose escalation methods in phase I cancer clinical trials|
C Le Tourneau, JJ Lee, LL Siu
JNCI: Journal of the National Cancer Institute 101 (10), 708-720, 2009
|Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong …|
AWM Lee, WH Lau, SY Tung, DTT Chua, R Chappell, L Xu, L Siu, ...
Journal of Clinical Oncology 23 (28), 6966-6975, 2005
|Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials|
CA Townsley, R Selby, LL Siu
Journal of clinical oncology 23 (13), 3112-3124, 2005
|Deintensification candidate subgroups in human papillomavirus–related oropharyngeal cancer according to minimal risk of distant metastasis|
B O'Sullivan, SH Huang, LL Siu, J Waldron, H Zhao, B Perez-Ordonez, ...
Journal of clinical oncology 31 (5), 543-550, 2013
|Toward understanding and exploiting tumor heterogeneity|
AA Alizadeh, V Aranda, A Bardelli, C Blanpain, C Bock, C Borowski, ...
Nature medicine 21 (8), 846, 2015
|Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial|
JJ Knox, D Hedley, A Oza, R Feld, LL Siu, E Chen, M Nematollahi, ...
Journal of Clinical Oncology 23 (10), 2332-2338, 2005
|A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas|
I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ...
British journal of cancer 95 (9), 1148-1154, 2006
|Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada|
X Chen, LL Siu
Journal of Clinical Oncology 19 (23), 4291-4297, 2001
|Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with …|
M Moore, HW Hirte, L Siu, A Oza, SJ Hotte, O Petrenciuc, F Cihon, ...
Annals of oncology 16 (10), 1688-1694, 2005
|Randomized trial of radiotherapy plus concurrent–adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma|
AWM Lee, SY Tung, DTT Chua, RKC Ngan, R Chappell, R Tung, L Siu, ...
Journal of the National Cancer Institute 102 (15), 1188-1198, 2010
|Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients|
MS Wu, P Johnston, WHH Sheu, CB Hollenbeck, CY Jeng, ID Goldfine, ...
Diabetes care 13 (1), 1-8, 1990
|Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma|
W Shi, H Kato, B Perez-Ordonez, M Pintilie, S Huang, A Hui, B O'Sullivan, ...
Journal of Clinical Oncology 27 (36), 6213-6221, 2009
|Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?|
KWL Yee, JL Pater, L Pho, B Zee, LL Siu
Journal of Clinical Oncology 21 (8), 1618-1623, 2003
|Raf kinase as a target for anticancer therapeutics|
SS Sridhar, D Hedley, LL Siu
Molecular cancer therapeutics 4 (4), 677-685, 2005
|Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas|
SH Huang, W Xu, J Waldron, L Siu, X Shen, L Tong, J Ringash, A Bayley, ...
J Clin Oncol 33 (8), 836-845, 2015
|Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting|
MH Kulke, LL Siu, JE Tepper, G Fisher, D Jaffe, DG Haller, LM Ellis, ...
Journal of Clinical Oncology 29 (7), 934, 2011